Evidence map›Paper›PMID 41555304›Full record

ArticleBMC public health2026

Tobacco advertising, cross-over effects, and US adolescent progression from never to current tobacco use.

Dennis R Trinidad, John P Pierce, Brian Dang, David R Strong, Matthew D Stone, Sara B McMenamin, Thet Nwe Myo Khin, Karen Messer

Abstract read
In one paragraph

Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dennis R TrinidadHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA. dtrinidad@health.ucsd.edu.
John P PierceHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
Brian DangHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
David R StrongHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
Matthew D StoneHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
Sara B McMenaminHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
Thet Nwe Myo KhinHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.
Karen MesserHerbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, California, 92093, USA.

Funding

Tobacco-Related Disease Research Program (TRDRP) of the University of California, Office of the President T31IR-1584Tobacco-Related Disease Research Program (TRDRP) of the University of California, Office of the President T32IR-4988
6 · The paper itself

Abstract

BACKGROUND AND

objectivesAdolescent receptivity to tobacco advertising has been linked to increased tobacco initiation in longitudinal studies. However, not all ever users progress to daily use. We examined whether receptivity to tobacco advertising among adolescents was associated with product-specific use, including daily use, as an adult, and whether receptivity to one product had a cross-over effect and predicted use of a different product at follow-up.

methodsIn the US Population Assessment of Tobacco and Health (PATH) Study, 74.6% of adolescent never-tobacco-users at baseline (2013-14) reported receptivity to tobacco advertising (for cigarettes, e-cigarettes, cigars, smokeless tobacco) and were surveyed on current tobacco use (every day, some days in past 30 days) an median of 7 years later (n = 7506). Multivariable logistic regression analyses included 8 common covariates.

resultsAt follow-up, 20.1% were current tobacco users (15.4% e-cigarettes) and 8.4% were daily users (6.5% e-cigarettes). Receptivity to any advertising at baseline was associated with current use (AOR = 1.46, 95%CI: 1.29,1.66) as well as daily use (AOR = 1.41, 95%CI: 1.16,1.72). Product-specific advertising was associated with current use of each product at follow-up and there was a cross-over effect with receptivity to product advertising associated with current use of a different product. This cross-over effect on progression to daily use was only seen for e-cigarettes (e-cigarette receptivity: AOR = 1.48, 95%CI: 1.19,1.84; cross-over receptivity: AOR = 1.55, 95%CI: 1.16,2.06). The usual e-cigarette device for current vapers at follow-up included disposables (37.6%), refillable tanks (27.9%) and cartridges (26.4%). Fruit/candy and menthol flavors were used most. JUUL was the most common e-cigarette brand and 29% of JUUL users recently vaped fruit/candy flavors.

conclusionsAmong adolescents who were receptive to tobacco advertising but had never used tobacco at baseline, there was significant progression to current and daily tobacco use 6.6 years later. The cross-over advertising effect went beyond the particular advertised product and effectively promoted daily nicotine use, particularly among 12-14-year-old adolescents at baseline, with progression to e-cigarettes. Population increases in adolescent progression to daily nicotine use is a public health harm that needs public health action to counteract the effectiveness of e-cigarette marketing both in schools and at the community level.

Indexed as

AdvertisingTobacco ProductsTobacco UseAdolescentCross-Over StudiesElectronic Nicotine Delivery SystemsFemaleHumansMaleUnited StatesAdolescentsAdvertisingCigarettesElectronic cigarettesReceptivityTobacco

Identifiers

PMID41555304
PMCPMC12895985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.